Related Experiment Video

Updated: May 30, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Targeted therapies: Improved outcomes for patients with metastatic melanoma

Vernon K Sondak1, Lawrence E Flaherty

  • 1Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. vernon.sondak@moffitt.org

Nature Reviews. Clinical Oncology
|July 27, 2011
PubMed

Insights

New phase III trials show interleukin-2, ipilimumab, and vemurafenib improve survival for metastatic melanoma patients, offering new first-line options beyond dacarbazine.

Area of Science:

  • Oncology
  • Immunotherapy
  • Dermatology

Background:

  • Metastatic melanoma treatment has historically relied on chemotherapy like dacarbazine.
  • Advances in targeted therapy and immunotherapy have led to new treatment paradigms.

Purpose of the Study:

  • To evaluate the efficacy of novel therapies including interleukin-2, ipilimumab, and vemurafenib.
  • To compare the survival outcomes of these agents against the established standard-of-care, dacarbazine.

Main Methods:

  • Analysis of recently published phase III clinical trials.
  • Comparison of treatment outcomes based on patient-specific factors such as tumor mutation status.

Main Results:

  • Interleukin-2, ipilimumab, and vemurafenib demonstrate improved survival rates compared to dacarbazine.
  • These therapies are emerging as viable first-line treatment options for metastatic melanoma.

Conclusions:

  • The standard-of-care for metastatic melanoma is being redefined by these novel therapeutic agents.
  • Treatment selection should be individualized based on tumor characteristics and patient status.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...